title: Soymorphin-5, a soy-derived μ-opioid peptide, decreases glucose and triglyceride levels through activating adiponectin and PPARα systems in diabetic KKAy mice.
abstract: Soymorphin-5 (YPFVV) derived from soybean β-conglycinin β-subunit is a μ-opioid agonist peptide having anxiolytic-like activity. Here, we show that soymorphin-5 improves glucose and lipid metabolism after long-term oral administration to KKAy mice, a type 2 diabetes model animal. Soymorphin-5 inhibited hyperglycemia without an increase in plasma insulin levels in KKAy mice. Soymorphin-5 also decreased plasma and liver triglyceride (TG) levels and liver weight, suggesting that soymorphin-5 improved lipid metabolism. Soymorphin-5 increased plasma adiponectin concentration and liver mRNA expression of AdipoR2, a subtype of adiponectin receptor that is involved in stimulating the peroxisome proliferator-activated receptor (PPAR)α pathway and fatty acid β-oxidation. The expressions of the mRNA of PPARα and its target genes acyl-CoA oxidase, carnitine palmitoyltransferase 1 A, and uncoupling protein-2, in the liver were also increased after oral administration of soymorphin-5. Furthermore, des-Tyr-soymorphin-5 (PFVV) without μ-opioid and anxiolytic-like activities did not decrease blood glucose levels in KKAy mice. These results suggest that μ-opioid peptide soymorphin-5 improves glucose and lipid metabolism via activation of the adiponectin and PPARα system and subsequent increases of β-oxidation and energy expenditure in KKAy mice.
authors: Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Gokasho Uji, Kyoto, Japan.
authors: Yuko
authors: Y
authors: Yamada
authors: Aya
authors: A
authors: Muraki
authors: Mariko
authors: M
authors: Oie
authors: Norimasa
authors: N
authors: Kanegawa
authors: Ayako
authors: A
authors: Oda
authors: Yurina
authors: Y
authors: Sawashi
authors: Kentaro
authors: K
authors: Kaneko
authors: Masaaki
authors: M
authors: Yoshikawa
authors: Tsuyoshi
authors: T
authors: Goto
authors: Nobuyuki
authors: N
authors: Takahashi
authors: Teruo
authors: T
authors: Kawada
authors: Kousaku
authors: K
authors: Ohinata
mesh_terms: D042962:Acyl-CoA Oxidase / Q000096:biosynthesis; D052242:Adiponectin / Q000819:agonists*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D002334:Carnitine O-Palmitoyltransferase / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006943:Hyperglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D007473:Ion Channels / Q000096:biosynthesis; D008099:Liver / Q000737:chemistry / Q000187:drug effects; D008297:Male; D051379:Mice; D024101:Mitochondrial Proteins / Q000096:biosynthesis; D018847:Opioid Peptides / Q000494:pharmacology*; D047493:PPAR alpha / Q000819:agonists*; D010446:Peptide Fragments / Q000494:pharmacology*; D054419:Receptors, Adiponectin / Q000096:biosynthesis; D030262:Soybean Proteins / Q000494:pharmacology*; D014280:Triglycerides / Q000037:antagonists & inhibitors* / Q000097:blood; D000071246:Uncoupling Protein 2
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D007473:Ion Channels; D024101:Mitochondrial Proteins; D018847:Opioid Peptides; D047493:PPAR alpha; D010446:Peptide Fragments; D054419:Receptors, Adiponectin; D030262:Soybean Proteins; D014280:Triglycerides; C000604390:Ucp2 protein, mouse; D000071246:Uncoupling Protein 2; C475421:adiponectin receptor 2, mouse; C571044:soymorphin-5; D042962:Acyl-CoA Oxidase; D002334:Carnitine O-Palmitoyltransferase